Smith Gregory Stephen sold $1.4M of TER

Smith Gregory Stephen (President and CEO) sold 4,000 shares of TERADYNE, INC (TER) at $337.83 ($1.35M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Smith Gregory Stephen
Published Sep 16, 2026, 4:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 4:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TER
Bearish
medium confidence
Mentioned
$TER
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TERBearishLow
01

Why it matters

The disclosed sale reduces the CEO's ownership, which may be interpreted as a negative signal, but the pre-arranged 10b5-1 plan tempers speculation.

02

Market read

The filing provides fresh insider activity data, offering a modest trading cue for TER.

03

What to watch

Potential upcoming earnings or strategic announcements could contextualize the sale.

Relevance 5/10Novelty 7/10Timing: post-market 2026-09-15

Background

Form 4 filings disclose insider transactions; a CEO sale often draws investor attention.

Company-level read

Ticker impact

$TERBearishMedium confidence
Context

CEO Stephen Smith sold 4,000 shares for $1.35M via a 10b5-1 plan, reducing his stake to 108,495 shares.

Expected impact

Possible modest downside pressure in the near term.

Evidence & confidence

The sale size is material for a mid-cap and executed under a pre-arranged plan, suggesting a neutral to slightly negative market reaction.

Market effects

Minimal impact on the broader medical device sector.

Limited to U.S. investors tracking insider activity.

Low

Counterpoint

The sale may be purely liquidity-driven, not indicative of company outlook.

Key entities

  • Stephen Smith

    President and CEO of Teradyne, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TERHigh

Teradyne and FormFactor jump after Jefferies starts coverage with Buy ratings

Jefferies initiated coverage of Teradyne and FormFactor with Buy ratings, citing their roles in AI-driven chip testing. Teradyne's stock rose 8.3% to $265.78, with a $284 target, while FormFactor gained 11.9% with a $102 target. Jefferies projects significant growth in the automated test equipment market, with Teradyne's revenue potentially rising from $1.9B to $6.9B by 2030. Both companies have seen recent pullbacks but reported strong AI-related revenue growth.

$TERHigh

Teradyne's AI testing opportunity prompts Jefferies 'buy' rating

Jefferies initiated coverage of Teradyne (NYSE:TER) with a Buy rating and $284 price target, citing AI-driven demand. The broker forecasts semiconductor testing market growth to $25B by 2030, with Teradyne's SoC testing revenue rising to $6.9B. Teradyne's shares fell 53% from summer highs, which Jefferies sees as an entry point. The bank expects Teradyne to gain market share and benefit from Nvidia's (NASDAQ:NVDA) adoption of dual sourcing.

$TERHigh

Why is Teradyne stock surging today?

Teradyne (TER) stock rose 8% in pre-market trading after Jefferies initiated coverage with a Buy rating and $284 price target, citing AI-driven growth. Analysts expect the semiconductor test equipment market to expand significantly, with TER benefiting from increased system-on-chip testing. The company's Q3 2026 earnings beat consensus, and broader tech sector gains also supported the surge.